Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes announced positive detailed results from the Phase 2 Vibrance-2 study of alixorexton in adults with narcolepsy type 2. The study met its dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements in wakefulness and excessive daytime sleepiness compared to placebo on the MWT and ESS scales.
Key figures
- Drug Name
- Alixorexton
- Phase Of Trial
- Phase 2
- Indication
- Narcolepsy Type 2 (NT2)
- Study name
- Vibrance-2
- Doses tested
- ["10 mg","14 mg","18 mg"]
- Patient count
- 93
- Ess p value 18mg
- p=0.046
- Mwt p value 14mg
- p=0.049
- Mwt p value 18mg
- p=0.047
- Completion rate ole
- ~90%
- Completion rate rdbt
- >95%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.